PDF(Pubmed)
Abstract：
OBJECTIVE: This modelling study aimed to estimate the burden for allergic diseases in children during a period of 30 years.
METHODS: Population-based observational study.
METHODS: The data on the incidence, mortality and disability-adjusted life years (DALYs) for childhood allergic diseases, such as atopic dermatitis (AD) and asthma, were retrieved from the Global Burden of Disease study 2019 online database. This data set spans various groups, including different regions, ages, genders and Socio-Demographic Indices (SDI), covering the period from 1990 to 2019.
RESULTS: In 2019, there were approximately 81 million children with asthma and 5.6 million children with AD worldwide. The global incidence of asthma in children was 20 million. Age-standardised incidence rates showed a decrease of 4.17% for asthma, from 1075.14 (95% uncertainty intervals (UI), 724.63 to 1504.93) per 100 000 population in 1990 to 1030.33 (95% UI, 683.66 to 1449.53) in 2019. Similarly, the rates for AD decreased by 5.46%, from 594.05 (95% UI, 547.98 to 642.88) per 100 000 population in 1990 to 561.61 (95% UI, 519.03 to 608.29) in 2019. The incidence of both asthma and AD was highest in children under 5 years of age, gradually decreasing with age. Interestingly, an increase in SDI was associated with a rise in the incidence of both conditions. However, the mortality rate and DALYs for asthma showed a contrasting trend.
CONCLUSIONS: Over the past three decades, there has been a worldwide increase in new asthma and AD cases, even though mortality rates have significantly declined. However, the prevalence of these allergic diseases among children varies considerably across regions, countries and age groups. This variation highlights the need for precise prevalence assessments. These assessments are vital in formulating effective strategies for prevention and treatment.
METHODS: Population-based observational study.
METHODS: The data on the incidence, mortality and disability-adjusted life years (DALYs) for childhood allergic diseases, such as atopic dermatitis (AD) and asthma, were retrieved from the Global Burden of Disease study 2019 online database. This data set spans various groups, including different regions, ages, genders and Socio-Demographic Indices (SDI), covering the period from 1990 to 2019.
RESULTS: In 2019, there were approximately 81 million children with asthma and 5.6 million children with AD worldwide. The global incidence of asthma in children was 20 million. Age-standardised incidence rates showed a decrease of 4.17% for asthma, from 1075.14 (95% uncertainty intervals (UI), 724.63 to 1504.93) per 100 000 population in 1990 to 1030.33 (95% UI, 683.66 to 1449.53) in 2019. Similarly, the rates for AD decreased by 5.46%, from 594.05 (95% UI, 547.98 to 642.88) per 100 000 population in 1990 to 561.61 (95% UI, 519.03 to 608.29) in 2019. The incidence of both asthma and AD was highest in children under 5 years of age, gradually decreasing with age. Interestingly, an increase in SDI was associated with a rise in the incidence of both conditions. However, the mortality rate and DALYs for asthma showed a contrasting trend.
CONCLUSIONS: Over the past three decades, there has been a worldwide increase in new asthma and AD cases, even though mortality rates have significantly declined. However, the prevalence of these allergic diseases among children varies considerably across regions, countries and age groups. This variation highlights the need for precise prevalence assessments. These assessments are vital in formulating effective strategies for prevention and treatment.
摘要：
目的：本模型研究旨在评估30年间儿童过敏性疾病的负担。
方法：基于人群的观察性研究。
方法：关于发病率的数据，儿童过敏性疾病的死亡率和残疾调整生命年(DALYs)，如特应性皮炎（AD）和哮喘，从2019年全球疾病负担研究在线数据库中检索。这个数据集跨越了不同的群体，包括不同的地区，年龄,性别和社会人口指数(SDI)，涵盖1990年至2019年期间。
结果：2019年，全球约有8100万哮喘儿童和560万AD儿童。全球儿童哮喘发病率为2000万。年龄标准化的哮喘发病率下降了4.17%，从1075.14(95%不确定度区间(UI)，724.63至1504.93)1990年每10万人口到1030.33(95%UI，683.66至1449.53），2019年。同样，AD的发病率下降了5.46%，从594.05(95%UI，547.98至642.88)1990年每10万人口至561.61(95%UI，519.03至608.29），2019年。哮喘和AD的发病率在5岁以下儿童中最高。随着年龄的增长逐渐减少。有趣的是,SDI的增加与两种疾病的发病率增加相关.然而,哮喘的死亡率和DALYs呈现对比趋势.
结论：在过去的三十年中，在全球范围内，新的哮喘和AD病例有所增加，尽管死亡率显著下降。然而,这些过敏性疾病在儿童中的患病率在不同地区之间差异很大，国家和年龄组。这种变化突出了对精确流行率评估的需要。这些评估对于制定有效的预防和治疗战略至关重要。
方法：基于人群的观察性研究。
方法：关于发病率的数据，儿童过敏性疾病的死亡率和残疾调整生命年(DALYs)，如特应性皮炎（AD）和哮喘，从2019年全球疾病负担研究在线数据库中检索。这个数据集跨越了不同的群体，包括不同的地区，年龄,性别和社会人口指数(SDI)，涵盖1990年至2019年期间。
结果：2019年，全球约有8100万哮喘儿童和560万AD儿童。全球儿童哮喘发病率为2000万。年龄标准化的哮喘发病率下降了4.17%，从1075.14(95%不确定度区间(UI)，724.63至1504.93)1990年每10万人口到1030.33(95%UI，683.66至1449.53），2019年。同样，AD的发病率下降了5.46%，从594.05(95%UI，547.98至642.88)1990年每10万人口至561.61(95%UI，519.03至608.29），2019年。哮喘和AD的发病率在5岁以下儿童中最高。随着年龄的增长逐渐减少。有趣的是,SDI的增加与两种疾病的发病率增加相关.然而,哮喘的死亡率和DALYs呈现对比趋势.
结论：在过去的三十年中，在全球范围内，新的哮喘和AD病例有所增加，尽管死亡率显著下降。然而,这些过敏性疾病在儿童中的患病率在不同地区之间差异很大，国家和年龄组。这种变化突出了对精确流行率评估的需要。这些评估对于制定有效的预防和治疗战略至关重要。
